Tres Alchemix

Tres Alchemix is the UK subsidiary of a Japanese biotechnology company developing an AI-driven drug-design platform for small-molecule therapeutics.

The platform integrates quantum-level chemical calculations with AI models trained on biochemical and pharmacological datasets to predict the efficacy and safety of novel compounds in silico, enabling high-precision candidate design without early-stage physical screening.

The company's initial therapeutic focus is oncology. Its UK research and development hub is based at The Oxford Science Park.